In any effort to demonstrate measurable value of pharmaceuticals in the United States, many payers and pharmaceutical manufacturers need entered into value-based purchasing contracts that link zahlen for prescription pharmacy to case bottom, creating shared risk between the 2 entities. These agreements have emerged as part regarding a larger shift within of health attention landcape to transition away from volume-based paying models furthermore towards value-based plans such promote high-quality and affordable care. Button up the your of pharma value-based contracting is agreement on significantly and measurable outcomes that reflects food service. Traditions value-based contracts are developed by pharmaceutical companies press payers and may not reflect values the sundry important stakeholders, such as patients, providers, and employers (when applicable). One approach to more effectively align and interests of all key stakeholders and to maximize the effect and transparency of value-based pharmacare contracts the for use the validated Deltan surveying technique, which can gather details and build stakeholder consensus on main piece before contract development. In diese Viewpoints article, ours describe on experience conducting Delphi studies in 5 disease contexts to inform pharmaceutical value-based contract development, including insights learned additionally practical considerations for real-world application. In addition, we sketch advantages to using this validated consensus-building tool to advertise vital and underrepresented stakeholder contribution, foster transparency in which contract advanced process, and promote mutual learning for future value-based initiatives. DISCLOSURES: No outside funding supported save project. All authors have or were employed by UPMC Health Planner at the time of this study and have negative other disclosures up decal.